Skip to main content
CGS Administrators, LLC

IVR: 866.238.9650 Customer Service and myCGS: 866.270.4909

July 18, 2019

Tumor Treatment Field Therapy (TTFT) Final LCD (L34823) and Response to Comments (RTC) Article Published

Joint DME MAC Publication

Today, the DME MACs published the Tumor Treatment Field Therapy (TTFT) Final LCD (L34823External Website) and LCD-related Policy Article (PA) (A52711External Website). The policy extends coverage of TTFT as a treatment option for Medicare beneficiaries with newly diagnosed glioblastoma multiforme (GBM). The posting of the final LCD marks the beginning of the 45-day notice period. The final LCD will be effective for claims with dates of service on or after September 1, 2019.

The DME MACs have also posted a response to all written comments received during the comment period, in a Response to Comments (RTC) Article (A56688)External Website.

Please refer to each DME MAC web site for additional information about policy development and copies of the final LCD.

26 Century Blvd Ste ST610, Nashville, TN 37214-3685 © CGS Administrators, LLC. All Rights Reserved